

Datasheet for ABIN2689553  
**anti-HLA-DM antibody**



[Go to Product page](#)

6 Publications

Overview

Quantity:	0.1 mg
Target:	HLA-DM
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This HLA-DM antibody is un-conjugated
Application:	Intracellular Staining (ICS)

Product Details

Brand:	BD Pharmingen™
Clone:	MaP-DM1
Isotype:	IgG1 kappa
Characteristics:	Reacts with human leukocyte antigen-DM (HLA-DM), a non-classical MHC class II molecule expressed in the cytoplasm of antigen presenting cells (APC). HLA-DM is composed of alpha and beta subunits which form a similar structure as the classical class II molecules. HLA-DM catalyzes the dissociation of CLIP from MHC class II-CLIP complexes in vitro and facilitates the binding of antigenic peptides. It also prevents self-antigens from becoming stably complexed with class II molecules and being presented to T cells. Profile of intracellular staining of peripheral blood lymphocytes analyzed on a FACScan . Profile of intracellular staining of peripheral blood monocytes analyzed on a FACScan .

BD Pharmingen™ Purified Mouse Anti-Human HLA-DM - Purified - Clone MaP.DM1 - Isotype

## Product Details

---

Mouse IgG1,  $\kappa$  - Reactivity Hu - 0.1 mg

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

## Target Details

---

Target: HLA-DM

Alternative Name: HLA-DM ([HLA-DM Products](#))

## Application Details

---

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

## Handling

---

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing  $\leq 0.09$  % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

## Publications

---

Product cited in: Litton, Sander, Murphy, OGarra, Abrams: "Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B." in: **Journal of immunological methods**, Vol. 175, Issue 1, pp. 47-58, (1994) ([PubMed](#)).

There are more publications referencing this product on: [Product page](#)